Spire Sciences Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$600,060	6
2024	Research	$838,160	9
2023	Research	$534,840	12
2022	Research	$1,124,160	7
2021	Research	$1,320,780	20
2020	Research	$1,577,600	31
2019	Research	$2,041,825	57

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $6,987,170 118 payments
EMD Serono, Inc. $963,575 19 payments
Ucb SA $39,110 2 payments
UCB Biosciences Inc. $25,020 2 payments
GlaxoSmithKline, LLC. $22,550 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) $1,269,840 13 payments
M15-572 $1,179,520 27 payments
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy $1,053,800 15 payments
Ms2005270060 $963,575 19 payments
M14-465 $682,500 13 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1 $674,640 8 payments
M16-011 $411,470 21 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1) $336,720 5 payments
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $320,160 1 payment
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy $309,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.